PubMed Health⌕ Search

PubMed · 3055958

Prognostic pathologic markers in IgA nephropathy.

Abstract

Previous studies have shown that the overall severity of the histologic grade and the extent of glomerular sclerosis are important pathologic markers of prognosis in IgA nephropathy. A previous analysis of the clinical and pathologic parameters in 74 patients at New York University Medical Center revealed that the renal survival (serum creatinine concentration of 2 mg/dL or less) was 100% in patients with mild proteinuria, 87% in those with moderate proteninuria, and 69% in those with heavy proteinuria. The incidence of segmental and global proliferation, glomerular sclerosis, tubulointerstitial damage, and vessel sclerosis increased with levels of proteinuria (P less than 0.01 to 0.05). A comparison of the morphologic parameters in 30 patients with similar initial serum creatinine concentrations (less than or equal to 2 mg/dL) but different outcomes demonstrates a greater incidence and severity of pathologic features, especially glomerular sclerosis in the "nonsurvival" than "survival" groups. Vessel sclerosis as quantitatively measured by a "point-count" technique correlates with the extent of glomerular sclerosis (r = 0.5192; P less than 0.001), suggesting a causal relationship or common basis.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

G R Gallo, R Katafuchi, K Neelakantappa, D S Baldwin. 1988. Prognostic pathologic markers in IgA nephropathy.. https://doi.org/10.1016/s0272-6386(88)80025-8

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Binding capacity of in vitro deglycosylated IgA1 to human mesangial cells.

IgA nephropathy (IgAN) is the most common glomerular disease and it is characterized by deposition of IgA1 molecules in mesangium. Recent studies had demonstrated that serum and mesangial IgA1 in IgAN were deglycosylated and IgA1 could bind to human mesangial cells (HMC) through a novel receptor. The aim of the current study is to investigate and compare the binding capacities of different in vitro deglycosylated IgA1 on human mesangial cells. Serum IgA1 was purified by jacalin affinity chromatography and then was desialylated (DesIgA1) and/or degalactosylated (Des/DeGalIgA1) with neuraminidase and/or beta-galactosidase. The efficacy of deglycosylations was assessed by Peanut agglutinin (PNA) and Vicia villosa (VV) lectin. The sizes of normal IgA1 and deglycosylated IgA1 were determined by Sephacryl S-300 chromatography and binding capacities to primary HMC were evaluated by radioligand binding assays. Normal IgA1 and deglycosylated IgA1 could bind to HMC in a dose-dependent, saturable manner. The maximal binding capacities and binding sites/cell of DesIgA1 and Des/DeGalIgA were significantly higher than that of normal IgA1. However, more aggregated IgA1 was found in DesIgA1 and Des/DeGalIgA1. Scatchard analysis revealed a similar Kd of normal IgA1 and deglycosylated IgA1. The current study suggested that the binding capacities of DesIgA1 and Des/DeGalIgA1 to HMC were significantly higher than that of normal IgA1, which at least in part was due to more macromolecular IgA1 in deglycoslated IgA1. However, there were no significant differences in the affinities of normal IgA1, DesIgA1 and Des/DeGalIgA1 with HMC. Deglycosylated IgA1 might play an important role in pathogenesis of IgAN.

Glomerulonephritis, IGA↗

The IgA nephropathy treatment dilemma.

Although IgA nephropathy (IgAN) is the most common form of primary glomerulonephritis worldwide, our understanding of the pathogenesis of this complex disease remains limited. IgA nephropathy may appear with a variety of clinical presentations, a number of different clinical and histopathologic risk factors for progressive renal disease, and a very variable course over time. Thus, it is not surprising that a single therapeutic treatment plan has not been established. Many of the studies dealing with IgAN are retrospective, lack statistical significance, or have confounding designs, which hinder their general acceptance. Nevertheless, a number of well-designed studies have been performed. This paper reviews currently available therapeutic options for IgAN. It attempts to address several important questions: Why do we treat patients with IgAN? How do we decide which patients should be treated? What are the general treatment guidelines for all IgAN patients? What is the role of specific therapy such as fish oils, tonsillectomy, and immunosuppression in the treatment of patient with IgAN? It also addresses several on-going trials and goals for future therapeutic studies for IgAN patients.

Glomerulonephritis, IGA↗